CL2019003270A1 - Carboxamidas de octa hidrofenantreno - bis y conjugados de proteína. - Google Patents

Carboxamidas de octa hidrofenantreno - bis y conjugados de proteína.

Info

Publication number
CL2019003270A1
CL2019003270A1 CL2019003270A CL2019003270A CL2019003270A1 CL 2019003270 A1 CL2019003270 A1 CL 2019003270A1 CL 2019003270 A CL2019003270 A CL 2019003270A CL 2019003270 A CL2019003270 A CL 2019003270A CL 2019003270 A1 CL2019003270 A1 CL 2019003270A1
Authority
CL
Chile
Prior art keywords
carboxamides
bis
octahydrophenanthrene
protein conjugates
conjugates
Prior art date
Application number
CL2019003270A
Other languages
English (en)
Inventor
William Olson
Amy Han
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62245504&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019003270(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2019003270A1 publication Critical patent/CL2019003270A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/90—Carboxylic acid amides having nitrogen atoms of carboxamide groups further acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the nitrogen atom of at least one of the carboxamide groups further acylated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

EN EL PRESENTE DOCUMENTO SE PROPORCIONAN COMPUESTOS, COMPOSICIONES Y MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS ASOCIADOS CON EL RECEPTOR X DEL HÍGADO, INCLUIDAS LAS BIS-OCTAHIDROFENANTRENO CARBOXAMIDAS Y SUS CONJUGADOS DE PROTEÍNAS (POR EJEMPLO, ANTICUERPOS).
CL2019003270A 2017-05-18 2019-11-14 Carboxamidas de octa hidrofenantreno - bis y conjugados de proteína. CL2019003270A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762508327P 2017-05-18 2017-05-18

Publications (1)

Publication Number Publication Date
CL2019003270A1 true CL2019003270A1 (es) 2020-05-08

Family

ID=62245504

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003270A CL2019003270A1 (es) 2017-05-18 2019-11-14 Carboxamidas de octa hidrofenantreno - bis y conjugados de proteína.

Country Status (16)

Country Link
US (2) US20180334426A1 (es)
EP (1) EP3625209A1 (es)
JP (2) JP2020520926A (es)
KR (1) KR20200008579A (es)
CN (1) CN111065622A (es)
AU (1) AU2018269568B2 (es)
BR (1) BR112019023990A2 (es)
CA (1) CA3063872A1 (es)
CL (1) CL2019003270A1 (es)
CO (1) CO2019014286A2 (es)
EA (1) EA201900562A1 (es)
IL (1) IL270595B2 (es)
MA (1) MA47392B1 (es)
MX (1) MX2019013693A (es)
PH (1) PH12019502576A1 (es)
WO (1) WO2018213082A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190074310A (ko) 2016-11-08 2019-06-27 리제너론 파마슈티칼스 인코포레이티드 스테로이드 및 이의 단백질-접합체
AU2018270784B2 (en) 2017-05-18 2024-05-16 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
SG11202004151YA (en) * 2017-11-07 2020-06-29 Regeneron Pharma Hydrophilic linkers for antibody drug conjugates
CA3098453A1 (en) 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof
CA3120528A1 (en) 2018-11-20 2020-05-28 Regeneron Pharmaceuticals, Inc. Bis-octahydrophenanthrene carboxamide derivatives and protein conjugates thereof for use as lxr agonists
MX2021008114A (es) * 2019-01-08 2021-08-05 Regeneron Pharma Enlazadores sin rastro y conjugados de proteinas de los mismos.
WO2021211984A1 (en) 2020-04-16 2021-10-21 Regeneron Pharmaceuticals, Inc. Diels-alder conjugation methods
WO2021260232A1 (en) * 2020-06-26 2021-12-30 Synaffix B.V. Methods for the preparation of linker payload constructs
CN116615257A (zh) 2020-11-10 2023-08-18 瑞泽恩制药公司 硒抗体缀合物
CN112661783B (zh) * 2020-12-28 2022-06-07 中国林业科学研究院林产化学工业研究所 一种硅氧烷二元松香基苯并环丁烯单体及其制备方法和应用
CN115006390B (zh) * 2022-06-27 2024-04-19 国药集团动物保健股份有限公司 一种病毒减毒制剂、其制备方法以及应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
CA2392568A1 (en) * 1999-12-13 2001-06-14 Merck & Co., Inc. Method for the prevention and/or treatment of atherosclerosis
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
US6908934B2 (en) * 2001-06-11 2005-06-21 Merck & Co., Inc. Therapeutic compounds for treating dyslipidemic conditions
AR048098A1 (es) 2004-03-15 2006-03-29 Wyeth Corp Conjugados de caliqueamicina
JP2008503547A (ja) * 2004-06-24 2008-02-07 ガラパゴス・ナムローゼ・フェンノートシャップ 骨ホメオスタシスを促進させる方法及び組成物
US7238791B1 (en) * 2005-12-16 2007-07-03 Roche Diagnostics Operations, Inc. 6-monoacetylmorphine derivatives useful in immunoassay
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
DK2167963T3 (da) 2007-05-23 2019-06-24 Ventana Med Syst Inc Polymerbærere til immunhistokemi og in situ-hybridisering
KR20100137585A (ko) 2008-04-30 2010-12-30 이뮤노젠 아이엔씨 강력한 복합체 및 친수성 링커
PE20130342A1 (es) 2010-04-15 2013-04-20 Spirogen Sarl Pirrolobenzodiacepinas y conjugados de las mismas
WO2012005982A2 (en) 2010-07-06 2012-01-12 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Reporter for rna polymerase ii termination
CN105399831A (zh) 2010-10-29 2016-03-16 伊缪诺金公司 非拮抗性egfr结合分子及其免疫偶联物
CN103702996A (zh) 2011-05-27 2014-04-02 Ambrx公司 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EA036202B1 (ru) 2011-10-14 2020-10-14 Сиэтл Дженетикс, Инк. Пирролбензодиазепины и конъюгаты направленного действия
EA029046B1 (ru) 2011-10-14 2018-02-28 Медимьюн Лимитед Пирролобензодиазепины и промежуточные соединения для их получения, способы их синтеза
BR112014008888A2 (pt) 2011-10-14 2017-04-18 Seattle Genetics Inc pirrolobenzodiazepinas
EP3388435B1 (en) 2011-10-14 2023-05-03 Seagen Inc. Pyrrolobenzodiazepines and targeted conjugates
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
SI2911699T1 (en) 2012-10-23 2018-04-30 Synaffix B.V. MODIFIED AGAINST, PROTITELO-KONJUGAT AND PROCESS FOR THEIR PREPARATION
CA2926698C (en) * 2013-10-15 2021-06-22 The California Institute For Biomedical Research Chimeric antigen receptor t cell switches and uses thereof
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
US20160324981A1 (en) * 2015-05-08 2016-11-10 The California Institute For Biomedical Research Liver x receptor agonists and uses thereof
US11786603B2 (en) 2016-02-26 2023-10-17 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
CA3098453A1 (en) * 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof

Also Published As

Publication number Publication date
US20220112158A1 (en) 2022-04-14
CN111065622A (zh) 2020-04-24
JP2023113639A (ja) 2023-08-16
EP3625209A1 (en) 2020-03-25
JP2020520926A (ja) 2020-07-16
WO2018213082A1 (en) 2018-11-22
BR112019023990A2 (pt) 2020-06-16
KR20200008579A (ko) 2020-01-28
PH12019502576A1 (en) 2020-09-28
AU2018269568B2 (en) 2022-03-24
AU2018269568A1 (en) 2020-01-16
US20180334426A1 (en) 2018-11-22
MX2019013693A (es) 2020-01-27
IL270595B2 (en) 2023-09-01
EA201900562A1 (ru) 2020-05-12
MA47392A1 (fr) 2020-10-28
MA47392B1 (fr) 2021-09-30
IL270595B1 (en) 2023-05-01
CO2019014286A2 (es) 2020-04-01
IL270595A (es) 2019-12-31
CA3063872A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
CL2019003270A1 (es) Carboxamidas de octa hidrofenantreno - bis y conjugados de proteína.
CL2019002304A1 (es) Compuestos para el tratamiento del cáncer.
ECSP18094857A (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
CO2018012946A2 (es) Moduladores de la vía de estrés integrada
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
CL2017000806A1 (es) Compuestos anti-tnf
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
ECSP17011657A (es) Conjugados de fármacos con anticuerpos anti-cdh6
CO2018001840A2 (es) Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5
ECSP17038999A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
CU20170018A7 (es) Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
CL2021001593A1 (es) Tubulisinas y conjugados de proteína-tubulisina
CL2017000087A1 (es) Un proceso novedoso para la purificación de rhu-gcsf
CL2017001310A1 (es) Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA201790893A1 (ru) Способы лечения офтальмологических расстройств
EA201692482A1 (ru) Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.